SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MRVT Miravant Med Tech: Infinity and Beyond? -- Ignore unavailable to you. Want to Upgrade?

To: Alan Gallaspy who wrote (60)1/15/2002 8:56:26 AM
From: Ian@SI  Read Replies (1) | Respond to of 67
 
Alan,

In the preceding post which was on Sept 12th, I asked,

"In a slide comparing industry participants, I saw a one-liner saying that SnET2 showed no
effectiveness after 12 months. I haven't seen anything directly from MRVT or Pharmacia.
Has anyone else seen anything recently, one way or the other? "

What is now surprising is that the industry has known that SnET2 wasn't effective for at least the past 4 months yet the stock price held up until yesterday's press release....



To: Alan Gallaspy who wrote (60)1/24/2002 11:52:29 AM
From: Marty Rubin  Respond to of 67
 
Alan,

Is there anything else promising for MRVT at this point?

I was planning to take a position in the stock ($1.27) assuming there's a whipeout (may happen since we have more limit sellers, ~10/1 ratio).

What I understand is that they have other clinical trials, and on top of cutting costs this company may survive beyond the one year.

Thank you,

Marty


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News